STATE OF THE CAR-T: Risk of Infections with CAR-T Therapy and Determinants of SARS-CoV-2 Vaccine Responses

Chimeric antigen receptor T-cells (CAR-T) are autologous T-cells re-directed towards a tumor-specific antigen and are a successful modality for patients with relapsed/refractory (R/R) hematological malignancies (HM)1-3. The engineered T-cells are transduced with a CAR molecule that consists of an antigen recognition single-chain variable fragment (scFv), a transmembrane domain, and an intracellular signaling domain, CD3 ζ. The intracytoplasmic and transmembrane portions of a second-generation CAR-T contain signaling domains of costimulatory receptors involved in T-cell activation and durability, such as CD3ζ, CD28, 4-1BB, ICOS, and OX40.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research